Not Signed In - La Jolla Pharmaceutical Provides Update On Phase 3 International Riquent(R) Study
Thu, 28 Sep 2006 07:00 AM EST
... La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today considerable progress on its Phase 3 trial of Riquent(R) (abetimus sodium) for the treatment of lupus renal disease. [click link for full article] ...
Related Topics
- International Health
- Tolterodine
- Yoga
- Phenylephrine and Guaifenesin ER Tablets
- Guaifenesin and Potassium Guaiacolsulfonate
- Phenylephrine and Guaifenesin Capsules
- Rue
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Psychopharmacology
- Pseudoephedrine and Guaifenesin ER
- Propranolol
- Retinoblastoma
- Peritoneal Dialysis
- Radiation Studies
- Diltiazem ER
- CHF
- Drug Information
- Pseudoephedrine and Guaifenesin
- International Classification of Diseases
email this page
print this page
bookmark this page
feedback on this page
